MDGL — Madrigal Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $10.20bn
- $9.56bn
- $958.40m
- 44
- 12
- 66
- 35
Annual income statement for Madrigal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 180 | 958 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 174 | 902 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 242 | 294 | 380 | 678 | 1,261 |
| Operating Profit | -242 | -294 | -380 | -498 | -303 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -242 | -295 | -374 | -466 | -288 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -242 | -295 | -374 | -466 | -288 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -242 | -295 | -374 | -466 | -288 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -242 | -295 | -374 | -466 | -288 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.6 | -17.2 | -20 | -21.9 | -12.7 |